Literature DB >> 16272208

Left ventricular hypertrophy in normoalbuminuric type 2 diabetic patients not taking antihypertensive treatment.

A Sato1, L Tarnow, F S Nielsen, E Knudsen, H-H Parving.   

Abstract

BACKGROUND: Left ventricular hypertrophy (LVH) is an independent risk factor for myocardial ischaemia, cardiac arrhythmia, sudden death, and heart failure, all common findings in patients with type 2 diabetes. AIM: To determine the prevalence of, and risk factors for, LVH in normoalbuminuric type 2 diabetic patients not taking antihypertensive treatment.
DESIGN: Cross-sectional study.
METHODS: From 1994 to 1998, M-mode echocardiography was performed by one experienced examiner in 262 consecutive, normoalbuminuric Caucasian type 2 diabetic patients, all with blood pressure <160/95 mmHg and not taking antihypertensive medication. Mean +/- SD age was 54 +/- 10 years, 109 were women, and median known duration of diabetes was 4 (range 1-28) years. Body mass index (BMI) was 28 +/- 5 kg/m(2), and blood pressure 134 +/- 13/79 +/- 8 mmHg, all means +/- SD. Median urinary albumin excretion rate was 9 (range 2-30) mg/24 h.
RESULTS: The prevalence of LVH indexed to height(2.7) was 43% (95%CI 38-50%), and was similar in men and women. BMI, HbA(1c) and log urinary albumin excretion were significantly associated with left ventricular hypertrophy in a logistic regression model, whereas sex, age, known duration of diabetes and blood pressure were not. Similar results were obtained for left ventricular mass index. DISCUSSION: LVH was frequent in our normoalbuminuric type 2 diabetic patients not taking antihypertensive treatment. Several potentially modifiable risk factors, such as raised BMI, poor glycaemic control and elevated urinary albumin excretion rate, were associated with LVH.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16272208     DOI: 10.1093/qjmed/hci137

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  8 in total

1.  Cardiac and renal function are progressively impaired with aging in Zucker diabetic fatty type II diabetic rats.

Authors:  John Baynes; David B Murray
Journal:  Oxid Med Cell Longev       Date:  2009 Nov-Dec       Impact factor: 6.543

2.  Comparison of left ventricular mass in normotensive type 2 diabetes mellitus patients with that in the nondiabetic population.

Authors:  Sukamal Santra; Asish Kumar Basu; Pradip Roychowdhury; Ramtanu Banerjee; Pankaj Singhania; Sudhakar Singh; Utpal Kumar Datta
Journal:  J Cardiovasc Dis Res       Date:  2011-01

3.  NT-proBNP, echocardiographic abnormalities and subclinical coronary artery disease in high risk type 2 diabetic patients.

Authors:  Henrik Reinhard; Peter R Hansen; Niels Wiinberg; Andreas Kjær; Claus L Petersen; Kaj Winther; Hans-Henrik Parving; Peter Rossing; Peter K Jacobsen
Journal:  Cardiovasc Diabetol       Date:  2012-03-05       Impact factor: 9.951

4.  Target organ damage and cardiovascular complications in patients with hypertension and type 2 diabetes in Spain: a cross-sectional study.

Authors:  Luis Cea-Calvo; Pedro Conthe; Pablo Gómez-Fernández; Fernando de Alvaro; Cristina Fernández-Pérez
Journal:  Cardiovasc Diabetol       Date:  2006-11-03       Impact factor: 9.951

5.  Cross-sectional analysis of serum calcium levels for associations with left ventricular hypertrophy in normocalcemia individuals with type 2 diabetes.

Authors:  Junfeng Li; Nan Wu; Yintao Li; Kuanping Ye; Min He; Renming Hu
Journal:  Cardiovasc Diabetol       Date:  2015-04-29       Impact factor: 9.951

6.  Association between insulin resistance and left ventricular hypertrophy in asymptomatic, Black, sub-Saharan African, hypertensive patients: a case-control study.

Authors:  Bernard Kianu Phanzu; Aliocha Nkodila Natuhoyila; Eleuthère Kintoki Vita; Jean-René M'Buyamba Kabangu; Benjamin Longo-Mbenza
Journal:  BMC Cardiovasc Disord       Date:  2021-01-02       Impact factor: 2.298

7.  The metal chelators, trientine and citrate, inhibit the development of cardiac pathology in the Zucker diabetic rat.

Authors:  John W Baynes; David B Murray
Journal:  Exp Diabetes Res       Date:  2009-04-15

Review 8.  Nutraceutical, Dietary, and Lifestyle Options for Prevention and Treatment of Ventricular Hypertrophy and Heart Failure.

Authors:  Mark F McCarty
Journal:  Int J Mol Sci       Date:  2021-03-24       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.